CN106501529A - A kind of chemiluminescence enzyme immunoassay kit of detection proto-oncogene HER2 and application - Google Patents

A kind of chemiluminescence enzyme immunoassay kit of detection proto-oncogene HER2 and application Download PDF

Info

Publication number
CN106501529A
CN106501529A CN201611023881.4A CN201611023881A CN106501529A CN 106501529 A CN106501529 A CN 106501529A CN 201611023881 A CN201611023881 A CN 201611023881A CN 106501529 A CN106501529 A CN 106501529A
Authority
CN
China
Prior art keywords
her2
solution
detection
proto
enzyme immunoassay
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201611023881.4A
Other languages
Chinese (zh)
Inventor
徐恒
陆上苏
李孟
陶艳茹
孙旭
赵灿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Jianan Medical Technology Co Ltd
Original Assignee
Nanjing Jianan Medical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Jianan Medical Technology Co Ltd filed Critical Nanjing Jianan Medical Technology Co Ltd
Priority to CN201611023881.4A priority Critical patent/CN106501529A/en
Publication of CN106501529A publication Critical patent/CN106501529A/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)

Abstract

The invention discloses a kind of chemiluminescence enzyme immunoassay kit of detection proto-oncogene HER2 and application, belong to field of immunological detection.Including box body, the Chemiluminescent plate being located in box body and the reagent being located in box body；Characterized in that, each hole of the Chemiluminescent plate is coated with Anti-HER 2；The reagent includes：HER2 serial standards solution, HER2 series quality-control products, biotin labeling Anti-HER 2, streptavidin HRP, Sample dilution, enzyme diluent, chemical luminous substrate A, B liquid, concentrated cleaning solution；The characteristics of chemical luminescence ELISA detection kit of the present invention has high sensitivity, simplicity is quick, accuracy is high, is compared with traditional ELISA method, and the operating time is greatly reduced.Can be used as the auxiliary diagnosis for detecting breast carcinoma.

Description

A kind of chemiluminescence enzyme immunoassay kit of detection proto-oncogene HER2 and application
Technical field
The present invention relates to a kind of chemiluminescence enzyme immunity of detection proto-oncogene ErbB-2 (HER2) (CLEIA) detection kit, for detecting the concentration of the HER2 albumen in Serum of Patients With Breast Cancer.Can be used as detecting breast carcinoma Auxiliary diagnosis.Belong to field of immunological detection.
Technical background
Proto-oncogene ErbB-2 (human epidermalgrowth factor receptor- 2, HER2) it is a kind of oncoprotein directly related with the biological characteristicses of cancer, has in the generation, evolution in breast carcinoma Important.
Breast carcinoma is the modal malignant tumor of women in worldwide, seriously threatens that numerous women's is healthy. , in trend is increased year by year, China's breast cancer incidence growth rate is fast in recent ten years, dead for China's female mammary gland cancer morbidity Rate occupies whole malignant tumor the 6th.
HER2 genes are also referred to as c-ErbB-2 genes, positioned at No. 17 chromosome q11-22 of people.The HER2 eggs of this gene code White matter molecular mass is about 185ku, and be otherwise known as p185HER2, with tyrosine kinase (TPK) activity, is human epidermal growth factor One of member of sub (EGF) receptor (EGFR) family.This family also includes EGFR (HER1/ErbB1), HER3 (ErbB3) and HER4 (tyro2 or ErbB4).The structure of HER2 can be divided into three regions, the i.e. ligand binding domain of cell surface, transmembrane region Domain, intracytoplasmic tyrosine kinase domain.The extracellular region of HER2 can come off into blood from breast cancer cell surface, can pass through one Determine the HER2 contents in method detection serum.
Have been reported that display, HER2 in the blood of Healthy People also can low expression, 25%～40% patient with breast cancer HER2 is in Overexpression, HER2 is in the blood of metastatic breast cancer patient in high expression.
Therefore, correctly judge that HER2 states contribute to assessing patient's prognosis, and be the important references for selecting therapeutic scheme Index.The features such as Serologic detection has convenience, real-time, seriality.Serum HER2 albumen becomes and instructs patient with breast cancer to face Bed medication and the potential tumor mark of evaluation prognosis
In consideration of it, it is significant to set up a kind of effective, quick, simple, sensitive detection HER2 method.
Content of the invention
It is an object of the invention to provide a kind of chemiluminescence enzyme immunoassay kit of HER2 and application.The test kit tool The characteristics of having that detection sensitivity is high, it is flexible to apply, facilitate, for detecting the concentration of the HER2 albumen in Serum of Patients With Breast Cancer.
For achieving the above object, present invention utilizes Chemiluminescence quantitative immunoassay, the method be chemoluminescence method and The product that enzyme-linked immunosorbent assay is combined, therefore has the height of the high sensitivity and immunoassay of chemoluminescence method special simultaneously Property.Double antibody sandwich method is the process employs, cardinal principle is that coated antibody is coated in formation insolubilized antibody in microwell plate, After standard substance, quality-control product, example reaction are added in micropore after coating, supernatant washing is abandoned, add the anti-of biotin labeling The detection antibody reaction of HER2, abandons supernatant washing, adds the reaction of HRP- streptavidins, ultimately forms insolubilized antibody and resists The anti-HER2 detection antibodies HRP- streptavidin complex of protozoa element labelling, adds luminescent solution A liquid, B liquid, at once reading Obtain RLU values.In whole course of reaction, in sample, HER2 contents are higher, and in reaction system, the stronger RLU values of luminous intensity are more High；Conversely, HER2 contents are fewer in sample, the weaker RLU values of luminous intensity are lower.
The invention provides chemiluminescence enzyme immunity (CLEIA) assay method of HER2 and its detection kit, including box Body, the Chemiluminescent plate being located in box body and the reagent being located in box body, including：
1. Chemiluminescent plate.For 96 hole of White-opalescent is detachable or non-removable polystyrene Chemiluminescent plate, respectively Hole is coated with the antibody of anti-HER2, and antibody coating concentration is 5.0 μ g/mL.
2.HER2 serial standards solution.Concentration is respectively：0、10、25、150、400、1000ng/mL.
3. quality-control product.Concentration is respectively：150±30、25±5ng/mL.
4. biotin labeling Anti-HER 2.Anti- as detection with the conjugate that biotin coupling is made by Anti-HER 2 Body.
5. the streptavidin of horseradish peroxidase (HRP) labelling.
6. Sample dilution.For 0.05mol/L phosphate buffers, pH=7.4, it is per liter and contains 8g NaCl, 0.2g KCl, 0.24g KH2PO4, 1.44g Na2HPO4Aqueous solution.
7. enzyme diluent：It is the 0.05mol/L phosphate buffers containing sucrose, pH=7.4 is per liter containing 50g sugarcanes Sugar, 8g NaCl, 0.2g KCl, 0.24g KH2PO4, 1.44g Na2HPO4Aqueous solution.
8. chemical luminous substrate A, B liquid.It is 0.001M pH=for 0.01M, p-cresol content that A liquid is luminol content 8.8 three (methylol) aminomethane solution；B liquid is every 100mL solution 2.1g containing citric acid, anhydrous Na2HPO42.82g, The aqueous solution of 0.75% carbamide peroxide 0.64mL, the percentage ratio are mass percent.
9. concentrated cleaning solution.Thickening and washing solution is specially 20 times of concentrations containing tween 20 (Tween-20) buffer Phosphate buffer, is used using front being diluted to after working concentration with distilled water, for washing chemistry luminous plaque in experimentation.
The preparation process of chemiluminescence enzyme immunity (CLEIA) detection kit for the HER2 that the present invention is provided is to present invention examination The sensitivity of agent box detection and correlated performance affect very greatly, and it is as follows which prepares committed step：
1. the preparation of pre-coated Chemiluminescent plate：Using Anti-HER 2 is placed in the coated solution of setting, to set Concentration, in 37 DEG C of calorstats react 2 hours coatings.The antibody coating concentration for adopting uses pH=for 5.0 μ g/mL 9.5 sodium carbonate sodium bicarbonate buffer solution.In microwell plate, the coated Anti-HER 2 of institute can be fine under alkaline environment Combination on microwell plate frosting, multiple board-washing can be stood.The microwell plate being coated can be closed with lock solution, React in 37 DEG C of calorstats 2 hours and close.
2.HER2 the preparation of serial standards solution：HER2 antigen solution concentrations are to determine HER2 enzyme linked immunologicals in the present invention Detection kit measurement range and the key factor of sensitivity.HER2 antigenic solutions can be diluted to 1 with antigenic dilution: 1000 working concentration, then according to doubling dilution method dilution antigen to final concentration of 0,10,25,150,400, The serial standards solution of 1000ng/mL.
The preparation of 3.HER2 series Quality Control solution：HER2 Quality Control solution concentrations are HER2 enzyme linked immunosorbent detection examinations in the present invention The key factor of agent box experimental implementation Quality Control.HER2 antigen sterling solution antigenic dilutions are diluted to 1:1000 work is dense Degree, is then diluted to the Quality Control solution of final concentration of 150,25ng/mL.
4. the preparation of biotin labeling Anti-HER 2：10 μ l traget antibodies add the biotin after 1 μ l dissolvings, use marking fluid 100 μ l are diluted to, are reacted 1 hour in 37 DEG C of water-baths, is then transferred in ready bag filter, is placed in dialysis solution, puts Dialysed on magnetic stirring apparatuss, dialysis solution needs 4～6h to change once, antibody after changing 5 times, can be received.
The present invention provide HER2 chemiluminescence enzyme immunity (CLEIA) detection kit in set and preparation process in Reagent solution sensitivity that test kit of the present invention is detected affect very big, the compound method of involved related solution is as follows：
1.HER2 standard solutions：With established methodology by HER2 sterling antigenic dilutions be configured to concentration be respectively 0, 10th, 25,150,400, the HER2 series standard solution of 1000ng/mL.
2.HER2 quality-control product solution：With established methodology by HER2 sterling antigenic dilutions be configured to concentration be respectively 150, The quality-control product solution of 25ng/mL.
3. biotin labeling Anti-HER 2：Biotin and antibody are carried out acquisition after coupling dialysis according to established methodology Biotin labeling Anti-HER 2, is diluted to 1 with antibody diluent:2000 working concentration is used as detection antibody.
4. antigenic dilution：It is that the 0.05mol/L phosphate buffers of sucrose, pH=7.4 are per liter and contain containing BSA 20g BSA, 50g sucrose, 8g NaCl, 0.2g KCl, 0.24g KH2PO4, 1.44g Na2HPO4Aqueous solution.
5. antibody diluent：It is the 0.05mol/L phosphate buffers containing sucrose, pH=7.4 is per liter and contains 50g Sucrose, 8g NaCl, 0.2g KCl, 0.24g KH2PO4, 1.44g Na2HPO4Aqueous solution.
6. Sample dilution：It is the 0.05mol/L phosphate buffers containing BSA, pH=7.4 is per liter and contains 20g BSA, 8g NaCl, 0.2g KCl, 0.24g KH2PO4, 1.44g Na2HPO4Aqueous solution.
7. enzyme diluent：It is the 0.05mol/L phosphate buffers containing sucrose, pH=7.4 is per liter containing 50g sugarcanes Sugar, 8g NaCl, 0.2g KCl, 0.24g KH2PO4, 1.44g Na2HPO4Aqueous solution.
8. chemiluminescent solution：It is 0.001M for 0.01M, p-cresol content that A liquid is luminol content, pH=8.8's Three (methylol) aminomethane solution, B liquid is every 100mL solution 2.1g containing citric acid, anhydrous Na2HPO42.82g, 0.75% The aqueous solution of carbamide peroxide 0.64mL.
9. thickening and washing solution：Tween 20 is added to pH=7.4,0.1mol/L phosphate by volume fraction 0.05% In buffer.
10. be coated solution：1.59g sodium carbonate and 2.53g sodium bicarbonate are dissolved in 1L water, adjust pH=9.5.
11. lock solutions：10g BSA are dissolved in 1L wash solutions, add the P300 that weight ratio is 5 ‰.
12. marking fluids：1.59g sodium carbonate and 2.53g sodium bicarbonate are dissolved in 1L water, adjust pH=9.5.
13. dialysis solution：0.24g sodium dihydrogen phosphate, 1.44g disodium hydrogen phosphates, 8g sodium chloride, 0.2g potassium chloride are dissolved in 1L water In, adjust PH=7.4.
The invention provides the detecting step of chemiluminescence enzyme immunity (CLEIA) assay method of HER2 is as follows：
1. using front, test kit all components are placed 20 minutes at room temperature, cleanout fluid (20 ×) is using front necessary 20 times are diluted with purified water, Streptavidin-HRP with using after 1000 times of enzyme diluted, deposit by lucifuge.
2. Chemiluminescent plate adds 200 μ l cleanout fluid using front per hole, gets rid of most cleanout fluid, and remove water droplet after waiting 30 seconds (patting dry in thick folded absorbent paper).Repeat this operation 2 times.
3. each to calibration object, quality-control product or serum sample 20 μ l are separately added in Chemiluminescent plate micropore, add sample 80 μ l of diluent, after concussion is mixed, with shrouding film shrouding, 37 DEG C of water-baths 10 minutes.
4. liquid in chemiluminescence plate hole is got rid of, adds 200 μ l cleanout fluid per hole, most cleanout fluid is got rid of after waiting 30 seconds, and gone Except water droplet (is patted dry in thick folded absorbent paper).Repeat this operation 5 times.
5. biotin labeling Anti-HER 2 is added, per 100 μ l of hole, with shrouding film shrouding, 37 DEG C of water-baths 30 minutes.
6. liquid in chemiluminescence plate hole is got rid of, adds 200 μ l cleanout fluid per hole, most cleanout fluid is got rid of after waiting 30 seconds, and gone Except water droplet (is patted dry in thick folded absorbent paper).Repeat this operation 5 times.
7. streptavidin-the HRP of 100 μ l is added, with shrouding film shrouding, 37 DEG C of water-baths 30 minutes.
8. liquid in chemiluminescence plate hole is got rid of, adds 200 μ l cleanout fluid per hole, most cleanout fluid is got rid of after waiting 30 seconds, and gone Except water droplet (is patted dry in thick folded absorbent paper).Repeat this operation 5 times.
9. (A, B liquid volume ratio is 1 to add 100 μ l luminescent solution A luminescent solution B mixed liquors:1) it is placed on Chemiluminescence Apparatus at once Reading, obtains RLU values.
10. it is coordinate axess according to the RLU values and concentration of standard substance, selects suitable Mathematical Models standard curve.Will The RLU values of sample, substitute in above-mentioned standard curve, draw concentration of specimens.
Relative to prior art, beneficial effects of the present invention are：The chemical luminescence ELISA detection kit of the present invention There is high sensitivity, the characteristics of easy quick, accuracy is high, compare with traditional ELISA method, the operating time is greatly reduced. Can be used as the auxiliary diagnosis for detecting breast carcinoma.
Description of the drawings：
Fig. 1：The principle summary figure of chemiluminescence enzyme immunity (CLEIA) detection kit of HER2
Fig. 2：The process chart of chemiluminescence enzyme immunity (CLEIA) detection kit of HER2.
Fig. 3：Standard curve for chemiluminescence enzyme immunity (CLEIA) detection kit of HER2
Fig. 4：Linear investigation result figure for chemiluminescence enzyme immunity (CLEIA) detection kit of HER2
Fig. 5：Chemiluminescence enzyme immunity (CLEIA) detection kit for HER2 determines the serum of patients serum and normal person The scatterplot of HER2 contents.
Specific embodiment
Embodiment one：Antibody and preferred (the square formation method) of envelope antigen concentration
The series of 80.0,40.0,20.0,10.0,5.0,2.5,1.25,0.625 μ g/mL is pressed with every kind of coated antibody in longitudinal direction Dilution factor coating Chemiluminescent plate, 100 μ L/ holes are placed in 37 DEG C of calorstats after 2 hours, pat dry；With 150 μ L/ holes lock solution envelopes Close, 37 DEG C of calorstats are placed 2 hours, and board-washing once, is patted dry；Add a series of HER2 antigens (1 of the dilutions in 100 μ L/ holes:1000 To 1:512000), (20～25 DEG C) of room temperature is incubated 30 minutes, and board-washing five times is patted dry for the last time；The anti-HER2 of regrowth element labelling Antibody, 37 DEG C of water-baths 30 minutes, board-washing five times is patted dry for the last time；Add streptavidin-HRP, 30 points of 37 DEG C of water-baths Clock, board-washing five times, is patted dry for the last time；(thinner ratio is 1 to be separately added into 100 μ l luminescent solution A luminescent solutions B mixed liquors:1), determine Luminous intensity values RLU value.There is the envelope antigen concentration of obvious graded with luminous intensity values with the concentration of envelope antigen and resist Body dilution factor carries out specific assay for optium concentration.
Determine according in the above-mentioned optimization experiment to coated antibody and antigen concentration, coated antibody concentration is 5.0 μ g/mL, The peak working concentration of antigen standard is 1:1000, i.e. 800ng/ml.
Embodiment two：The standard curve of chemiluminescence enzyme immunity (CLEIA) detection kit of HER2
According to the detecting step of chemiluminescence enzyme immunity (CLEIA) assay method of HER2, HER2 serial standards are obtained Luminous value RLU.It is coordinate axess according to the RLU values and concentration of standard substance, selects suitable Mathematical Models standard curve,
Standard curve is as shown in Fig. 2 its correlation coefficient r=0.9999.
The accuracy of chemiluminescence enzyme immunity (CLEIA) detection kit of three HER2 of embodiment
According to the detecting step of chemiluminescence enzyme immunity (CLEIA) assay method of HER2, take definite value sample and detected. After repeated measure 3 times, its average result is designated as M, according to the relative deviation of formula (1) computation and measurement concentration.
B=(M-T)/T × 100% formula (1)
In formula：
B relative deviations；
M measures the meansigma methodss of 3 results of concentration；
The concentration of T definite value samples.
As shown in table 1, its relative deviation is 4.54% to accuracy result, less than 10%, shows the test kit in detection sample This when, has preferable accuracy：
Table 1：
Example IV：The lowest detectable limit of chemiluminescence enzyme immunity (CLEIA) detection kit of HER2
Detected as sample that with zero-dose sample replication 20 times draws the luminous value value of 20 measurement results (RLU values), calculates its meansigma methods (M) and standard deviation (SD), draws the RLU values corresponding to M+2SD, is calibrated according to used by test kit The calibration curve equation of product, the RLU values corresponding to M+2SD is brought in above-mentioned equation, is obtained corresponding concentration value, is as detected Limit.
As shown in table 2, detection is limited to 1.18ng/ml to test limit result.
Table 2：
Embodiment five：HER2 chemiluminescence enzyme immunity (CLEIA) detection kit linear
The high level sample for being close to the range of linearity upper limit is diluted at least 5 kinds concentration by a certain percentage with Sample dilution, Wherein low value concentration samples must be close to the lower limit of the range of linearity.By each concentration samples duplicate detection 2 times, the flat of its concentration is calculated Concentration of specimens after result meansigma methodss and dilution is carried out fitting a straight line, and calculates linear correlation system by average with method of least square Number r.
Linear investigate figure as shown in figure 3, its r=0.9969, correlation coefficient is more than 0.9900, test kit linear dependence compared with Good.
Embodiment six：The repeatability of chemiluminescence enzyme immunity (CLEIA) detection kit of HER2
With each duplicate detection of the sample of two concentration levels 10 times, meansigma methodss M and the mark of 10 measurement concentration results is calculated Quasi- difference SD, draws coefficient of variation CV according to formula (2).
CV=SD/M × 100% formula (2)
In formula：
The CV coefficient of variation；
The standard deviation of 10 measurement results of SD；
The meansigma methodss of 10 measurement results of M.
As shown in table 3, coefficient of variation CV is respectively less than 10% to repeated result, shows that the test kit has when sample is detected Preferably repeated：
Table 3：
Embodiment six：The clinical sample detection case of chemiluminescence enzyme immunity (CLEIA) detection kit of HER2
According to the detecting step of chemiluminescence enzyme immunity (CLEIA) assay method of HER2,29 patient's (mammary gland are have selected Carninomatosis people), the serum sample of 33 normal persons (crowd of the clinical diagnosises without breast cancer disease) is detected, is obtained serum The concentration value of middle HER2, draws scatterplot.
Shown in measurement result Fig. 4, the concentration value of HER2 in the serum of the patient and normal person of the kit measurement, with bright The significant difference opposite sex, concentration average of the concentration average of HER2 apparently higher than HER2 in serum in patients serum.The test kit is a kind of Preferable HER2 concentration measuring kits.
The invention discloses the chemiluminescence enzyme immunity of a kind of proto-oncogene ErbB-2 (HER2) (CLEIA) detection kit, test kit are used for the concentration for detecting the HER2 albumen in Serum of Patients With Breast Cancer.Can be used as detection breast The auxiliary diagnosis of adenocarcinoma.The fit standard curve correlation coefficient of the test kit up to r=0.9999, more than 0.9900；With respect to inclined Difference is 4.54%, less than 10%；Detection is limited to 1.18ng/ml；Linear investigate, the correlation coefficient r of concentration value fitting a straight line= 0.9969, correlation coefficient is more than 0.9900；Coefficient of variation CV of repeated result is respectively less than 10%；It is being applied to clinical sample Normal person and patient can be significantly distinguished in detection.The test kit illustrates good accuracy, linear, repeated, minimum Test limit, the ability with the good concentration for determining the HER2 albumen in serum, can be used as the auxiliary diagnosis of detection breast carcinoma. The test kit of the present invention dries lucifuge at 2～8 DEG C and can preserve 6 months, and transport under the conditions of 2～8 DEG C can keep performance in 72 hours Stable.
The above is only the preferred embodiment of the present invention, it should be pointed out that：Ordinary skill people for the art For member, under the premise without departing from the principles of the invention, some improvements and modifications can also be made, these improvements and modifications also should It is considered as protection scope of the present invention.

Claims (10)

1. a kind of chemiluminescence enzyme immunoassay kit of detection proto-oncogene HER2, including box body, the change being located in box body Learn luminous plaque and the reagent being located in box body, it is characterised in that：Chemiluminescent plate is coated with the antibody of anti-HER2；Reagent includes： HER2 serial standards solution, HER2 series quality-control product solution, Sample dilution, biotin labeling Anti-HER 2, Radix Cochleariae officinalises mistake Oxide enzyme（HRP）The streptavidin of labelling, enzyme diluent, chemiluminescent solution A, B liquid, thickening and washing solution.
2. the chemiluminescence enzyme immunoassay kit of detection proto-oncogene HER2 according to claim 1, its feature exist In：Chemiluminescent plate is the opaque 96 hole Chemiluminescent plate of polystyrene of milky, and each hole is coated with the antibody of anti-HER2, antibody Coated concentration is 5.0 μ g/mL.
3. the chemiluminescence enzyme immunoassay kit of detection proto-oncogene HER2 according to claim 1, its feature exist In：The detection sample behaviour serum sample of test kit.
4. the chemiluminescence enzyme immunoassay kit of detection proto-oncogene HER2 according to claim 1, its feature exist In：HER2 serial standards solution concentrations are respectively：0、10、25、150、400、1000 ng/mL；HER2 series quality-control product solution Concentration is respectively：150±30、25±5ng/mL.
5. the chemiluminescence enzyme immunoassay kit of detection proto-oncogene HER2 according to claim 4, its feature exist In：Sample dilution is 0.05 mol/L phosphate buffers, pH=7.4, be per liter containing 16 g NaCl, 0.4 g KCl, 0.4 g KH2PO4, 5.8 g Na2HPO4Aqueous solution.
6. the chemiluminescence enzyme immunoassay kit of detection proto-oncogene HER2 according to claim 5, its feature exist In：Enzyme diluent：It is the 0.05 mol/L phosphate buffers containing sucrose, pH=7.4 is per liter containing 50 g sucrose, 8 g NaCl, 0.2 g KCl, 0.24 g KH2PO4, 1.44 g Na2HPO4Aqueous solution.
7. the chemiluminescence enzyme immunoassay kit of detection proto-oncogene HER2 according to claim 6, its feature exist In：Thickening and washing solution is the pH=7.4 containing 0.05 % tween 20s of volume fraction, 0.1 mol/L phosphate buffers.
8. the chemiluminescence enzyme immunoassay kit of detection proto-oncogene HER2 according to claim 6, its feature exist In：Chemiluminescent solution A liquid is three (methylols) that luminol content is 0.01M, p-cresol content is 0.001M pH=8.8 Aminomethane solution；B liquid is every 100 mL solution 2.1g containing citric acid, anhydrous Na2HPO42.82g, 0.75% hydrogen peroxide The aqueous solution of 0.64 mL of urea, the percentage ratio are mass percent.
9. the chemiluminescence enzyme immunoassay kit of detection proto-oncogene HER2 according to claim 1, its feature exist In：Described reagent includes：
HER2 standard solutions：HER2 sterling antigenic dilutions are configured to concentration and are respectively 0,10,25,150,400,1000 The HER2 series standard solution of ng/mL；
HER2 quality-control product solution：HER2 sterling antigenic dilutions are configured to the quality-control product that concentration is respectively 150,25 ng/mL Solution；
Biotin labeling Anti-HER 2：The anti-HER2 of biotin labeling that biotin and antibody carry out obtaining after coupling dialysis is resisted Body, is diluted to 1 with antibody diluent:2000 working concentration is used as detection antibody；
Antigenic dilution：It is containing BSA, 0.05 mol/L phosphate buffers of sucrose, pH=7.4, is per liter and contains 20 g BSA, 50 g sucrose, 8 g NaCl, 0.2 g KCl, 0.24 g KH2PO4, 1.44 g Na2HPO4Aqueous solution；
Antibody diluent：Be the 0.05 mol/L phosphate buffers containing sucrose, pH=7.4, be per liter containing 50 g sucrose, 8 G NaCl, 0.2 g KCl, 0.24 g KH2PO4, 1.44 g Na2HPO4Aqueous solution；
Sample dilution：Be the 0.05 mol/L phosphate buffers containing BSA, pH=7.4, be per liter containing 20 g BSA, 8 G NaCl, 0.2 g KCl, 0.24 g KH2PO4, 1.44 g Na2HPO4Aqueous solution；
Enzyme diluent：It is the 0.05 mol/L phosphate buffers containing sucrose, pH=7.4 is per liter containing 50 g sucrose, 8 g NaCl, 0.2 g KCl, 0.24 g KH2PO4, 1.44 g Na2HPO4Aqueous solution；
Chemiluminescent solution：A liquid be luminol content be 0.01M, p-cresol content be 0.001M, the three (hydroxyls of pH=8.8 Methyl) aminomethane solution, B liquid is every 100mL solution 2.1g containing citric acid, anhydrous Na2HPO42.82g, 0.75% peroxidating The aqueous solution of hydrogen urea 0.64mL；
Thickening and washing solution：Tween 20 is added to pH=7.4 by volume fraction 0.05%, 0.1 mol/L phosphate buffers In；
Coated solution：1.59 g sodium carbonate and 2.53 g sodium bicarbonate are dissolved in 1 L water, adjust pH=9.5；
Lock solution：10 g BSA are dissolved in 1L wash solutions, add the P300 that weight ratio is 5 ‰；
Marking fluid：1.59 g sodium carbonate and 2.53 g sodium bicarbonate are dissolved in 1 L water, adjust pH=9.5；
Dialysis solution：0.24 g sodium dihydrogen phosphate, 1.44g disodium hydrogen phosphates, 8g sodium chloride, 0.2g potassium chloride are dissolved in 1L water, are adjusted Section PH=7.4.
10. application of the test kit described in claim 1-9 any one as Computer-aided Diagnosis of Breast Cancer reagent.
CN201611023881.4A 2016-11-17 2016-11-17 A kind of chemiluminescence enzyme immunoassay kit of detection proto-oncogene HER2 and application Pending CN106501529A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201611023881.4A CN106501529A (en) 2016-11-17 2016-11-17 A kind of chemiluminescence enzyme immunoassay kit of detection proto-oncogene HER2 and application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201611023881.4A CN106501529A (en) 2016-11-17 2016-11-17 A kind of chemiluminescence enzyme immunoassay kit of detection proto-oncogene HER2 and application

Publications (1)

Publication Number Publication Date
CN106501529A true CN106501529A (en) 2017-03-15

Family

ID=58327259

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201611023881.4A Pending CN106501529A (en) 2016-11-17 2016-11-17 A kind of chemiluminescence enzyme immunoassay kit of detection proto-oncogene HER2 and application

Country Status (1)

Country Link
CN (1) CN106501529A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108548930A (en) * 2018-03-30 2018-09-18 迈克生物股份有限公司 Corticotropin chemiluminescence detection kit
CN108828216A (en) * 2018-04-03 2018-11-16 江苏省肿瘤防治研究所（江苏省肿瘤医院） A kind of NTN-4 chemiluminescence enzyme immunological quantitative determining kit and application
CN109734799A (en) * 2018-07-23 2019-05-10 深圳市伯劳特生物制品有限公司 A kind of application of expression and the method and Her2 full-length proteins that purify Her2 full-length proteins
CN111965361A (en) * 2020-08-05 2020-11-20 上海长征医院 Chemiluminescence kit for quantitatively detecting human chitinase 3-like protein 1

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1397803A (en) * 2001-07-13 2003-02-19 中国科学技术大学 Method for detecting human tumor antigen P 185 Her-2 and its application in diagnosing tumor
US7732157B1 (en) * 1999-09-30 2010-06-08 Tumor Biology Investment Group Soluble epidermal growth factor receptor-like proteins and their uses in cancer detection methods
CN103575900A (en) * 2012-07-23 2014-02-12 苏州长光华医生物试剂有限公司 Kit used for detecting ERBB2 protein, and preparation method thereof
CN103698536A (en) * 2013-12-20 2014-04-02 安徽安科生物工程（集团）股份有限公司 Oncoprotein P185 detection kit
CN104122394A (en) * 2013-04-23 2014-10-29 北京豪迈生物工程有限公司 Quantitative determination kit and detection method for human epidermal growth factor receptor 2(Her-2)
CN105866418A (en) * 2016-06-03 2016-08-17 广州华弘生物科技有限公司 Triple test diagnostic kit for breast cancer
CN106124754A (en) * 2016-08-31 2016-11-16 镇江华测金太医学检验所有限公司 A kind of application process preparing VEGF reagent

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732157B1 (en) * 1999-09-30 2010-06-08 Tumor Biology Investment Group Soluble epidermal growth factor receptor-like proteins and their uses in cancer detection methods
CN1397803A (en) * 2001-07-13 2003-02-19 中国科学技术大学 Method for detecting human tumor antigen P 185 Her-2 and its application in diagnosing tumor
CN103575900A (en) * 2012-07-23 2014-02-12 苏州长光华医生物试剂有限公司 Kit used for detecting ERBB2 protein, and preparation method thereof
CN104122394A (en) * 2013-04-23 2014-10-29 北京豪迈生物工程有限公司 Quantitative determination kit and detection method for human epidermal growth factor receptor 2(Her-2)
CN103698536A (en) * 2013-12-20 2014-04-02 安徽安科生物工程（集团）股份有限公司 Oncoprotein P185 detection kit
CN105866418A (en) * 2016-06-03 2016-08-17 广州华弘生物科技有限公司 Triple test diagnostic kit for breast cancer
CN106124754A (en) * 2016-08-31 2016-11-16 镇江华测金太医学检验所有限公司 A kind of application process preparing VEGF reagent

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108548930A (en) * 2018-03-30 2018-09-18 迈克生物股份有限公司 Corticotropin chemiluminescence detection kit
CN108548930B (en) * 2018-03-30 2021-11-09 迈克生物股份有限公司 Chemiluminescence detection kit for corticotropin
CN108828216A (en) * 2018-04-03 2018-11-16 江苏省肿瘤防治研究所（江苏省肿瘤医院） A kind of NTN-4 chemiluminescence enzyme immunological quantitative determining kit and application
CN109734799A (en) * 2018-07-23 2019-05-10 深圳市伯劳特生物制品有限公司 A kind of application of expression and the method and Her2 full-length proteins that purify Her2 full-length proteins
CN111965361A (en) * 2020-08-05 2020-11-20 上海长征医院 Chemiluminescence kit for quantitatively detecting human chitinase 3-like protein 1

Similar Documents

Publication Publication Date Title
CN106501529A (en) A kind of chemiluminescence enzyme immunoassay kit of detection proto-oncogene HER2 and application
CN109580958A (en) The fluorescence and colorimetric dual signal detection kit and detection method of a kind of cardiac muscle troponin I
CN101603966A (en) A kind of male multi-tumor marker detection protein chip and kit thereof
CN205333645U (en) Lp -PLA2 quick quantitative detection test paper strip in people's serum
CN101178405B (en) Tumor-associated antigen 50 chemiluminescence immune analyze quantitative determination reagent box and method of producing the same
CN109187973A (en) For detecting the chemiluminescence immunoassay kit of neuronspecific enolase
CN109001472A (en) Human thyrotropin receptor antibody chemical luminescence detection kit and preparation method thereof and application method
CN106959372A (en) Serum amyloid A protein and the two-in-one measure kit of C reactive proteins and preparation method
CN106124754A (en) A kind of application process preparing VEGF reagent
CN108613977A (en) A kind of N-terminal plasma pro-brain natriuretic peptide levels detection kit and its detection method
CN102226808A (en) Trypsinogen-2 chemiluminescent immunoassay kit and preparation method thereof
CN106990254A (en) 25 hydroxycholecalciferols determine kit and preparation method
CN106405106A (en) Chemiluminescence enzyme-linked immunosorbent assay kit of central nervous specific protein
CN109061176A (en) A kind of total Type I collagen aminoterminal of detection serum extends the kit and application method of peptide
CN105492907B (en) New detection method
CN101692085A (en) Method for quantitatively detecting TRAb plate-type fluorescent enzyme immunity and application thereof
CN110488004A (en) A kind of 25-hydroxy-vitamin D kit and its preparation method and application for detecting peripheral blood
CN107389955A (en) The immune colloid gold detection means and detection method of HCG detection ranges can be widened
CN102749461B (en) Free β human chorionic gonadotrophin chemiluminescence immunoassay immue quantitative detection reagent box and preparation method thereof
CN102095868A (en) Alpha fetoprotein chemiluminescence quantitive detection kit
CN106460056A (en) Novel method for detecting detection object in sample, and detection kit using same
CN106645717A (en) Kit for rapidly detecting chlamydia trachomatis and gonorrhea and application of kit
CN106370841A (en) Chemiluminiscence enzyme-linked immunosorbent assay reagent kit for golgin 73
CN105158474A (en) Reagent kit for detecting serum HER2 and application
CN106353508A (en) Chemiluminescent enzyme-linked immunosorbent assay kit for bladder tumor-associated antigens

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20170315